Nikhil Prasad Fact checked by:Thailand Medical News Team Sep 16, 2026 43 minutes ago
A key immune molecule involved in activating T cells could become an important new target for diagnosing and treating atherosclerosis, according to a detailed review of experimental and human evidence.
Targeting the immune molecule CD80 could open new approaches to detecting and controlling dangerous
inflammatory atherosclerotic plaques.
Researchers Alexander Blagov, Aleksey Vatlin, Daria Borodko, and Anastasia Maksaeva are from the Laboratory of Molecular Genetic Modeling of Inflammaging, Institute of General Pathology and Pathophysiology, Moscow, Russia. Their review examined evidence showing that CD80, also known as B7-1, plays a complex role in inflammation inside arterial plaques.
Atherosclerosis Is More Than Cholesterol
Atherosclerosis was once viewed mainly as cholesterol and other lipids accumulating inside arteries. It is now understood as a chronic immune-inflammatory disease in which immune cells actively influence plaque formation, progression, and instability.
CD80 is particularly important because it helps control T-cell activity. It interacts with CD28 to promote T-cell activation but also binds CTLA-4, which restrains immune responses. CD80 can additionally interact with PD-L1, placing the molecule at the center of several immune-checkpoint pathways.
The researchers found that CD80 is expressed by dendritic cells, macrophages, foam cells, B cells, and, during inflammation, endothelial and vascular smooth muscle cells. Importantly, human carotid artery samples showed significantly higher CD80 and related immune markers in unstable, symptomatic plaques than in stable, asymptomatic plaques.
Blocking the Immune Signal Shows Promise
Among the strongest findings highlighted in this
Thailand Medical News report were results from experimental treatments that interfered with CD80/CD86 signaling.
Abatacept, a CTLA-4-Ig drug that blocks CD28 interactions with CD80 and CD86, reduced intimal thickening by 58.5% in a mouse vascular-injury model and reduced accelerated atherosclerosis by 78.1% in hypercholesterolemic ApoE3*Leiden mice. Treatment was also associated with reduced CD4+ T-cell activation, lower inflammatory interferon-gamma, and increased anti-inflammatory interleukin-10.
More selective targeting may offer another route. RhuDex, a small-molecule inhibitor specifically targeting CD80, reduced the inflammatory mediators TNF-alpha, IL-6, and CCL2 in cultured human carotid plaque tissue while also suppressing T-cell activation.
Human observational evidence is also encouraging. In rheumatoid arthritis patients, abatacept was associated with a 20% lower composite cardiovascular risk than TNF inhibitors, with an especially strong association among patients with diabetes. However, no randomized clinical trial has yet directly tested CD80/CD86 blockade as an atherosclerosis treatment.
CD80 Could Also Help Identify Dangerous Plaques
CD80 may have diagnostic potential. Experimental PET and SPECT imaging agents targeting CD80/CD86 accumulated in atherosclerotic plaques, while binding in huma
n carotid tissue correlated with immune-cell infiltration and large necrotic cores—features associated with vulnerable plaques.
Conclusions
The evidence positions CD80 as a promising but still experimental cardiovascular target. Selectively controlling this immune pathway could potentially reduce harmful plaque inflammation while preserving beneficial immune regulation, but prospective human studies and randomized trials are essential before CD80-directed therapies can become established treatments.
The study findings were published in the peer reviewed International Journal of Molecular Sciences.
https://www.mdpi.com/1422-0067/27/18/8215
Read Also:
https://www.thailandmedical.news/articles/cardiology 
Share
Tweet
Share
